Cancer Research The Future of Cancer Research: Science and Patient Impact  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 51, 4865-4870, September 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kushner, B. H.
Right arrow Articles by Cheung, N.-K. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kushner, B. H.
Right arrow Articles by Cheung, N.-K. V.

Clinically Effective Monoclonal Antibody 3F8 Mediates Nonoxidative Lysis of Human Neuroectodermal Tumor Cells by Polymorphonuclear Leukocytes1

Brian H. Kushner2 and Nai-Kong V. Cheung

Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Most studies of antibody-dependent cellular cytotoxicity (ADCC) by polymorphonuclear leukocytes (PMN) have supported oxidative lytic processes. This may be because the studies used nonhuman or nonneoplastic cells that were highly sensitive to reactive oxygen species or were small enough to be phagocytosed by PMN. We therefore investigated whether oxygen radicals participate in PMN cytotoxicity toward human neuroectodermal solid tumor cells sensitized by 3F8, which is an antiganglioside GD2 murine IgG3 monoclonal antibody with documented anticancer activity in humans. A 4-h 51Cr release assay was used to assess tumor cell lysis by hydrogen peroxide, superoxide, and hypochlorite. Nine of 11 GD2(+) human melanoma and neuroblastoma cell lines had equal or greater resistance to these oxidants as compared to a GD2(-) human carcinoma line (SKBr1-III) found by others (and confirmed by us) to be significantly more resistant to oxidative lysis than a murine cell line (P388D1) representative of those commonly used in cytotoxicity assays. To facilitate detection of oxidant-mediated lysis, subsequent studies of 3F8-mediated ADCC used GD2(+) targets that were relatively sensitive and others that were relatively resistant to oxygen radicals. Normal PMN and PMN obtained from children with chronic granulomatous disease, which do not generate reactive oxygen species, were equally effective in ADCC. Granulocyte-macrophage colony-stimulating factor, which primes oxidative responses of normal but not of chronic granulomatous disease PMN, enhanced ADCC by both kinds of PMN. During ADCC of 3F8-sensitized targets, with or without granulocyte-macrophage colony-stimulating factor, GD2(-) "innocent bystander" tumor cells (including P388D1) were not lysed, a finding consistent with unimportant extracellular release of cytotoxic mediators. Finally, antioxidant and antimyeloperoxidase moieties did not block ADCC. We conclude that oxidants are not key factors in 3F8-mediated lysis by PMN of human neuroectodermal tumor cells.

1 This work was supported by grants from the American Cancer Society (IM521 and CDA90-242), the National Cancer Institute (CA33049), the Robert Steel Foundation, and the Justin Zahn Fund. B. H. K. is a recipient of an American Cancer Society Career Development Award. Presented in part at the 32nd Annual Meeting of the American Society of Hematology, Boston, MA, November 28–December 4, 1990.

2 To whom requests for reprints should be addressed, at Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.

Received 4/15/91. Accepted 7/ 8/91.




This article has been cited by other articles:


Home page
JCOHome page
N.-K. V. Cheung, R. Sowers, A. J. Vickers, I. Y. Cheung, B. H. Kushner, and R. Gorlick
FCGR2A Polymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor
J. Clin. Oncol., June 20, 2006; 24(18): 2885 - 2890.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Wagner, C. Iking-Konert, B. Denefleh, S. Stegmaier, F. Hug, and G. M. Hansch
Granzyme B and perforin: constitutive expression in human polymorphonuclear neutrophils
Blood, February 1, 2004; 103(3): 1099 - 1104.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
L. Ottonello, A. L. Epstein, M. Mancini, M. Amelotti, P. Dapino, and F. Dallegri
Monoclonal Lym-1 antibody-targeted lysis of B lymphoma cells by neutrophils. Evidence for two mechanisms of Fc{gamma}RII-dependent cytolysis
J. Leukoc. Biol., November 1, 2000; 68(5): 662 - 668.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1991 by the American Association for Cancer Research.